NASDAQ:MDRX
Allscripts Healthcare Solutions Stock News
$7.95
-0.0800 (-1.00%)
At Close: Apr 25, 2024
Dexcom's (DXCM) CGM Gets FDA's Breakthrough Device Designation
05:10pm, Friday, 04'th Mar 2022 Zacks Investment Research
Dexcom's (DXCM) CGM's use in the hospital setting is likely to be more effective in glycemic management and improved patient outcomes.
Benzinga's Top Ratings Upgrades, Downgrades For March 4, 2022
03:04pm, Friday, 04'th Mar 2022 Benzinga
Upgrades
According to Susquehanna, the prior rating for Knight-Swift Transportation Holdings Inc (NYSE:KNX) was changed from Neutral to Positive. Knight-Swift earned $1.61 in the fourth quarter, compa
Benzinga''s Top Ratings Upgrades, Downgrades For March 4, 2022
03:04pm, Friday, 04'th Mar 2022 Benzinga
Upgrades According to Susquehanna, the prior rating for Knight-Swift Transportation Holdings Inc (NYSE: KNX ) was changed from Neutral to Positive. Knight-Swift earned $1.61 in the fourth quarter, compared to $0.94 in the year-ago quarter. The stock has a 52-week-high of $62.29 and a 52-week-low of $43.53. At the end of the last trading period, Knight-Swift closed at $54.76. According to 86 Research, the prior rating for Weibo Corp (NASDAQ: WB ) was changed from Hold to Buy. In the fourth quarter, Weibo showed an EPS of $0.83, compared to $0.92 from the year-ago quarter. At the moment, the stock has a 52-week-high of $64.70 and a 52-week-low of $26.47. Weibo closed at $27.28 at the end of the last trading period. For HEXO Corp (NASDAQ: HEXO ), Canaccord Genuity upgraded the previous rating of Hold to Speculative Buy. HEXO earned $0.46 in the first quarter, compared to $0.04 in the year-ago quarter. The stock has a 52-week-high of $8.50 and a 52-week-low of $0.46. At the end of the last trading period, HEXO closed at $0.60.
A Peek Into The Markets: US Stock Futures Down; Jobs Report In Focus
11:27am, Friday, 04'th Mar 2022 Benzinga
Pre-open movers
U.S. stock futures traded lower in early pre-market trade after the Nasdaq dipped more than 200 points in the previous session. The Zaporizhzhia nuclear power plant in Ukraine — Euro
Henry Schein (HSIC) Hits 52-Week High: What's Aiding the Stock?
05:02pm, Thursday, 03'rd Mar 2022 Zacks Investment Research
Investors are optimistic about Henry Schein's (HSIC) favorable dental business trends.
Veeva (VEEV) Beats on Q4 Earnings, Narrows '23 Revenue View
03:10pm, Thursday, 03'rd Mar 2022 Zacks Investment Research
Veeva Systems' (VEEV) fiscal Q4 results reflect impressive performances by both of its segments.
Allscripts Divests Hospitals & Large Physician Practices Segment For $700M
02:15pm, Thursday, 03'rd Mar 2022 Benzinga
Allscripts Healthcare Solutions (NASDAQ: MDRX ) will sell its net assets of the Allscripts Hospitals and Large Physician Practices business segment to Constellation Software Inc''s subsidiary N. Harris Computer Corporation. The Hospitals and Large Physician Practices business segment includes the Sunrise, Paragon, Allscripts … Full story available on Benzinga.com
Allscripts selling hospitals physician practices segments to Constellation Software (MDRX)
10:35pm, Wednesday, 02'nd Mar 2022 Seeking Alpha
Allscripts Healthcare Solutions (MDRX) is selling the net assets of its hospitals and large physician practices segments to a subsidiary of Constellation Software.
Masimo's (MASI) SedLine Receives FDA's Pediatric Indication
04:13pm, Wednesday, 02'nd Mar 2022 Zacks Investment Research
The latest FDA clearance for Masimo's (MASI) SedLine is likely to improve brain function monitoring in pediatric patients.
Inogen (INGN) Stock Surges 16.5% Despite Q4 Earnings Miss
02:10pm, Tuesday, 01'st Mar 2022 Zacks Investment Research
Inogen's (INGN) fourth-quarter results benefit from higher revenues across the majority of its geographical segments.
OPKO Health's (OPK) Q4 Earnings Miss Estimates, Revenues Top
05:00pm, Monday, 28'th Feb 2022 Zacks Investment Research
OPKO Health's (OPK) fourth-quarter results benefit from continued strength in its Pharmaceuticals segment.
Merit Medical's (MMSI) Q4 Earnings, Revenues Top Estimates
04:05pm, Monday, 28'th Feb 2022 Zacks Investment Research
Merit Medical (MMSI), in the fourth quarter, benefits from revenue growth in both its segments, and from majority of the product categories within its Cardiovascular unit.
Allscripts Healthcare Solutions: Fundamentals Are Improving, But Consistency Needs To Be Established
03:04pm, Sunday, 27'th Feb 2022 Seeking AlphaAllscripts' (MDRX) Q4 Earnings Beat Estimates, Margins Up
03:19pm, Friday, 25'th Feb 2022 Zacks Investment Research
Allscripts' (MDRX) robust Q4 results demonstrate strength in both segments.